

USSN 10/730,781

CT-2758 NP

Remarks

Status of the claims. Claims 1-11 are pending. Claims 12-16 were canceled. Claims 8 and 9 were rejected under 35 USC 112, second paragraph. Claims 11-16 were rejected under 35 USC 112, first paragraph.

Rejection under 35 USC 112, second paragraph. Claims 8 and 9 were rejected for being indefinite. Claim 8 has been rewritten in Independent form adding the variables of allowed claim 1. Claim 9 has been rewritten to be properly dependent on claim 1, that is, the variables of claim 9 were defined to be those of claim 1. If there are any further issues with these claims, the applicants authorize the examiner to make an amendment to put them in allowable form.

Rejection under 35 USC 112, first paragraph. Claims 11-16 were rejected under 35 USC 112, first paragraph for being enabled for epilepsy but not enabled for other diseases or conditions. Because the examiner stipulated that a treatment for epilepsy was enabled, the applicants amended claim 11 to be a method for the treatment of epilepsy and cancelled the remaining method of treatment claims.

The applicants believe the application is now in allowable form and respectfully request favorable reconsideration. If any issues remain regarding the allowance of this application, the Examiner is respectfully invited to contact the applicants' agent, James Epperson, by phone (203-677-6974), fax (203-677-6900), or e-mail (james.epperson@bms.com).

Respectfully submitted,

Date: 3/17/2005
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

James Epperson
James Epperson
Agent for Applicants
Reg. No. 52,867
Phone: (203) 677-6974